Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Virpax Pharmaceuticals

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Regains Compliance with Nasdaq Minimum Bid Price
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Updates on Litigation
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces CFO Transition
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Reports on Progress of Envelta™
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pursues OTC Medical Device Pathway for AnQlar™
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications
From Virpax Pharmaceuticals
Via Business Wire
Tickers VRPX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.